ljpc

[myis denovo]

aggiornamento.
ljpc vendera' circa 5mln di azioni sul mercato allo scopo di finanziarsi il programma lavori almeno fino al 2009.una diluzione qualcuno ha detto di circa il 15%.sembra che il mercato lo abbia scontato gia' in abbondanza tanto che la LJPC è finita in SHO. passera'.non credo che qusta volta finira come nel 2004 e che la festa verra' fatta' si ma agli shorters.oggi lo vedremo .se risale lo fara' di un bel po'.spero almeno..va be niente cifre.
particolare non secondario...non si sa' a quanto rilasceranno le nuove shares ..magari 10$?? o piu' ?o meno?.



spero sia gradito.

 

[RW1392]

Con uno stop stretto, al livello di ema 10 (area $ 6.70) si puo' provare un ingresso.
Sotto a $ 5.91 un importante supporto, sopra a $ 9 una resistenza di pari grado.

Ciao

 

[RW1392]

Ciao

aggiornamento.
ljpc vendera' circa 5mln di azioni sul mercato allo scopo di finanziarsi il programma lavori almeno fino al 2009.

particolare non secondario...non si sa' a quanto rilasceranno le nuove shares ..magari 10$?? o piu' ?o meno?.

Press Release Source: La Jolla Pharmaceutical Company


La Jolla Pharmaceutical Company Announces Pricing of Common Stock Offering
Thursday March 29, 10:24 pm ET


SAN DIEGO, March 29 /PRNewswire-FirstCall/ -- La Jolla Pharmaceutical Company (Nasdaq: LJPC - News) today announced the pricing of an underwritten public offering of 5,800,000 shares of its common stock at $6.00 per share for a total offering of $34.8 million. All of the shares are being sold by the Company. The offering is expected to close on April 4, 2007, subject to customary closing conditions. The Company has granted the underwriters an option to purchase up to an additional 870,000 shares to cover over-allotments in the offering, if any.



This press release does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering may be made only by means of a prospectus supplement and the accompanying prospectus.

This offering is being made pursuant to an effective shelf registration statement. Needham & Company, LLC acted as sole lead bookrunning manager for the offering. A.G. Edwards & Sons, Inc. acted as a co-manager. A final prospectus supplement and the accompanying base prospectus will be filed with the Securities and Exchange Commission and will be available on the SEC's website at http://www.sec.gov. Copies of the final prospectus supplement and accompanying base prospectus may be obtained, when available, upon making a request in writing to Needham & Company, LLC, 445 Park Avenue, New York, New York 10022.

This press release contains "forward-looking statements" within the meaning of federal securities law. The forward-looking statements in this press release are subject to numerous risks and uncertainties, including the risk the offering may not be completed as described herein, or at all.